КЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИ РОССИЙСКОЙ ГАСТРОЭНТЕРОЛОГИЧЕСКОЙ АССОЦИАЦИИ И АССОЦИАЦИИ КОЛОПРОКТОЛОГОВ РОССИИ ПО ДИАГНОСТИКЕ И ЛЕЧЕНИЮ БОЛЕЗНИ КРОНА

1. Sandborn W.J., Feagan B.G., Hanauer S.B., Lochs H., Löfberg R., Modigliani R. et al. A review of activity indices and efficacy endpoints for clinical trials of medical therapy in adults with Crohn’s disease. Gastroenterology. - 2002; 122: 512-30.

2. Reinisch W., Rutgeerts P., Panaccione R., D’Haens G., Thakkar R., Yu A. Identifying appropriate dichotomizing points for SES-CD to predict long-term clinical remission for adalimumab - treated patients with Crohn’s disease. J. Crohns Colitis. - 2010; 4: P045

3. Воробьев Г.И., Халиф И.Л. Неспецифические воспалительные заболевания кишечника. Миклош. -2008.

4. Khor B., Gardet A., Xavier R.J. Genetics and pathogenesis of inflammatory bowel disease. Nature. -2011; 474: 307-17.

5. Гастроэнтерология. Национальное руководство / Под ред. Ивашкина В.Т., Лапиной Т. Л. ГЭОТАР Медиа. - 2008. - 754 c.

6. Cosnes J., Gower-Rousseau C., Seksik P., Cortot A. Epidemiology and natural history of inflammatory bowel diseases. Gastroenterology. - 2011; 140: 1785-94.

7. Silverberg M.S., Satsangi J., Ahmad T., Arnott I.D., Bernstein C.N., Brant S.R. et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can. J. Gastroenterol. - 2005; 19 (Suppl A): 5-36.

8. Cosnes J., Cattan S., Blain A., Beaugerie L., Carbonnel F., Parc R. et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm. Bowel. Dis. - 2002; 8: 244-50.

9. Белоусова Е.А. Рекомендации по диагностике и лечению болезни Крона. Фарматека. - 2009. -№ 13. - с. 38-44.

10. Best W.R., Becktel J.M., Singleton J.W., Kern F. Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology. 1976. - Mar; 70 (3): 439-44.

11. Horsthuis K., Bipat S., Bennink R.J., Stoker J. Inflammatory bowel disease diagnosed with US, MR, scintigraphy, and CT: metaanalysis of prospective studies. Radiology. - 2008; 247 (1): 64-79.

12. Чашкова Е.Ю., Владимирова А.А., Неустроев В.Г. и соавт. Воспалительные заболевания толстой кишки - аспекты диагностики. Бюллетень Восточно-Сибирского научного центра СО РАМН. - 2011. - № 4-2. - с. 209-221.

13. Lennard-Jones J.E. Classification of inflammatory bowel disease. Scand. J. Gastroenterol. Suppl. - 1989; 170: 2-6.

14. Григорьева Г.А., Мешалкина Н.Ю. О проблеме системных проявлений воспалительных заболеваний кишечника. Фарматека. - 2011. - № 15. -с. 44-49.

15. Issa M., Ananthakrishnan A.N., Binion D.G. Clostridium difficile and inflammatory bowel disease. Inflamm. Bowel Dis. - 2008; 14: 1432-42.

16. Nguyen G.C., Kaplan G.G., Harris M.L. et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am. J. Gastroenterol. - 2008; 103: 1443-50.

17. Воробьев Г.И., Орлова Л.П., Самсонова Т.В., Капуллер Л.Л., Михайлова Т.Л., Халиф И.Л. Возможности ультразвукового исследования в диагностике болезни крона. Ультразвуковая и функциональная диагностика. - 2010. - № 1. - с. 29-36.

18. Cheifetz A.S., Kornbluth A.A., Legnani P. et al. the risk of retention of the capsule endoscope in patients with known or suspected Crohn’s disease. Am. J. Gastroenterol. - 2006; 101: 2218-22.

19. Spada C., Riccioni M.E., Costamagna G. Patients with known small bowel stricture or with symptoms of small bowel obstruction secondary to Crohn’s disease should not perform video capsule endoscopy without previously tested for small bowel patency. Am. J. Gastroenterol. - 2007; 102: 1542-3.

20. Spada C., Shah S.K., Riccioni M.E. et al. Video capsule endoscopy in patients with known or suspected small bowel stricture previously tested with the dissolving patency capsule. J. Clin. Gastroenterol. -2007; 42: 576-82.

21. Тертычный А.С., Андреев А.И., Гебоэс К. Современные подходы к морфологической диагностике воспалительных заболеваний кишечника на материале эндоскопических биопсий. Архивпатологии. - 2011. - т. 73. - №1. - с. 40-47.

22. American Gastroenterological Association medical position statement: guidelines for the evaluation and management of chronic diarrhea. Gastroenterology. -1999; 116 (6): 1461-3.

23. Корнеева О.И., Ивашкин В.Т. Антибиотикоассоциированный колит: патоморфология, клиника, лечение. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2007. -т. 17. - № 3. - с. 65-71.

24. Gert Van Assche, Axel Dignass, Julian Panes et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Current management. Journal of Crohn’s and Colitis. -2010; 4, 28-58.

25. Carter M.J., Lobo A.J., Travis S.P. IBD Section, British Society of Gastroenterology. Guidelines for the management of inflammatory bowel disease in adults. Gut. - 2004; 53 (Suppl 5): V1-V16.

26. Simms L., Steinhart A.H. Budesonide for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. - 2001: CD002913.

27. Tay G.S., Binion D.G., Eastwood D., Otterson M.F. Multivariate analysis suggests improved perioperative outcome in Crohn’s disease patients receiving immunomodulator therapy after segmental resection and/or strictureplasty. Surgery. - 2003; 34: 565-72 discussion 572-3.97.

28. Steinhart A.H., Ewe K., Griffiths A.M., Modigliani R., Thomsen O.O. Corticosteroids for maintaining remission of Crohn’s disease. Cochrane Database Syst. Rev. - 2003 (4): CD000301.

29. Benchimol E.I., Seow C.H., Steinhart A.H., Griffiths A.M. Traditional corticosteroids for induction of remission in Crohn’s disease. Cochrane Database Syst. Rev. - 2008; 2: CD006792.

30. Ho G.T., Chiam P., Drummond H., Loane J., Arnott I.D., Satsangi J. The efficacy of corticosteroid therapy in inflammatory bowel disease: analysis of _ a 5-year UK inception cohort. Aliment. Pharmacol. Ther. - 2006; 24: 319-30

31. Lémann M., Mary J.Y., Duclos B. et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. - 2006; 130: 1054-61.

32. Sandborn W., Sutherland L., Pearson D. et al. Azathioprine or 6-mercaptopurine for inducing remission of Crohn’s disease. Cochrane Database Syst. Rev. - 2000 (2): CD000545.

33. Frey B.M., Frey F.J. Clinical pharmacokinetics of prednisone and prednisolone. Clin. Pharmacokinet. -1990 Aug; 19 (2): 126-46.

34. Sandborn W.J., Feagan B., Radford-Smith G. et al. CDP571, a humanised monoclonal antibody to tumour necrosis factor alpha, for moderate to severe Crohn’s disease: a randomised, double blind, placebo controlled trial. Gut. - 2004; 53: 1485-93.

35. Feagan B., Sandborn W.J., Baker J.P. et al. A randomized, doubleblind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn’s disease. Aliment. Pharmacol. Ther. - 2005; 21: 373-84.

36. Pearson D.C., May G.R., Fick G.R., Sutherland L.R. Azathioprine for maintaining remission of Crohn’s disease. Cochrane Database Syst. Rev. - 2000 (2): CD000067.

37. Prefontaine E., Sutherland L.R., MacDonald J.K. et al. Azathioprine or 6-mercaptopurine formaintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. - 2009; 1: CD000067.

38. Bresci G., Petrucci A., Banti S. 5-aminosalicylic acid in the prevention of relapses of Crohn’s disease in remission: a longterm study. Int. J. Clin. Pharmacol. Res. - 1991; 11: 200-2.

39. Lémann M., Mary J.Y., Duclos B., et al. Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology. - 2006; 130: 1054-61.

40. Malchow H., Ewe K., Brandes J.W. et al. European co-operative Crohn’s disease study (ECCDS): results of drug treatment. Gastroenterology. - 1984; 86: 249-66.

41. Colombel J.F., Rutgeerts P., Reinisch W. et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naïve to immunomodulators and biologic therapy. Gut. -2008; 57 Suppl. II: A1.

42. Behm B.W., Bickston S.J. Tumor necrosis factor-alpha antibody for maintenance of remission in Crohn’s disease. Cochrane Database Syst. Rev. -2009; 1: CD006893.

43. Alfadhli A.A., McDonald J.W., Feagan B.G. Methotrexate for induction of remission in refractory Crohn’s disease (Cochrane Review). Cochrane Database Syst. Rev. - 2003 (1): CD003459.

44. Candy S., Wright J., Gerber M. et al. A controlled double blind study of azathioprine in the management of Crohn’s disease. Gut. - 1995; 37: 674-9.

45. D’Haens G., Baert F., van Assche G. et al. Belgian Inflammatory Bowel Disease Research Group; North-Holland Gut Club. Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. Lancet. - 2008; 371: 660-7.

46. Khan K.J., Ullman T.A., Ford A.C., Abreu M.T., Abadir A., Abadir A. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. - 2011; 106: 661-73.

47. Ohkusa T., Kato K., Terao S., Chiba T., Mabe K., Murakami K. et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am. J. Gastroenterol. - 2010; 105: 1820-9.

48. Khan K.J., Ullman T.A., Ford A.C. et al. Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am. J. Gastroenterol. -2011; 106: 661-73.

49. Scand J. Gastroenterol. Suppl. - 1998; 225: 92-9. Azathioprine: state of the art in inflammatory bowel disease. Sandborn WJ.

50. Rutgeerts P., Feagan B.G., Lichtenstein G.R. et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn’s disease. Gastroenterology. - 2004; 126: 402-13.

51. Colombel J.F., Rutgeerts P., Reinisch W. et al. SONIC: a randomized, double blind, controlled trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn’s disease naïve to immunomodulators and biologic therapy. Gut. -2008; 57 Suppl. II: A1.

52. Strong S.A., Koltun W.A., Hyman N.H., Buie W.D. Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the surgical management of Crohn’s disease. Dis. Colon Rectum. - 2007; 50: 1735-46.

53. Справочник по колопроктологии под редакцией проф. Шелыгина Ю.А., проф. Благодарного Л.А. «Литтерра». - 2012. - с. 460-522.

54. Хачатурова Э.А., Ерошкина Т.Д., Блинова О.В. и соавт. Коррекция нарушений метаболизма в раннем послеоперационном периоде при тяжелых формах неспецифического язвенного колита и болезни Крона. «Российский журнал гастроэнтерологии, гепатологии, колопроктологии». - 2003. - т. 8. -№ 4. - с. 63-68.

55. Korzenik J.R. Massive lower gastrointestinal hemorrhage in Crohn’s disease. Curr. Treat Options Gastroenterol. - 2000; 3: 211-6.

56. Bundred N.J., Dixon J.M., Lumsden A.B., Gilmour H.M., Davies G.C. Free perforation in Crohn’s colitis. A ten-year review. Dis. Colon Rectum. - 1985; 28: 35-7.

57. Werbin N., Haddad R., Greenberg R., Karin E., Skornick Y. Free perforation in Crohn’s disease. Isr. Med. Assoc. J. - 2003; 5: 175-7.

58. Papi C., Festa V., Fagnani C., Stazi A., Antonelli G., Moretti A. et al. Evolution of clinical behaviour in Crohn’s disease: predictive factors of penetrating complications. Dig. Liver Dis. - 2005; 37: 247-53.

59. Poggioli G., Stocchi L., Laureti S., Selleri S., Marra C., Magalotti C. et al. Conservative surgical management of terminal ileitis: side-to-side enterocolic anastomosis. Dis Colon Rectum. - 1997; 40: 234-7.

60. Melton G.B., Fazio V.W., Kiran R.P., He J., Lavery I.C., Shen B. et al. Long-term outcomes with ileal pouch-anal anastomosis and Crohn’s disease: pouch retention and implications of delayed diagnosis. Ann. Surg. - 2008; 248: 608-16.

61. Варданян А.В., Кашников В.Н., Болихов К.В., Халиф И.Л. Лапароскопическая илеостомия при болезни Крона. Журнал «Колопроктология». -2011. - №3 (37). - с. 20-23.

62. Воробьев Г.И., Болихов К.В., Варданян А.В. Место лапароскопической илеостомии в лечении болезни Крона толстой кишки (обзор литературы). Колопроктология. - 2009. - №3 (29). - с. 52-58.

63. Sagar P.M., Dozois R.R., Wolff B.G. Long-term results of ileal pouch-anal anastomosis in patients with Crohn’s disease. Dis. Colon Rectum. - 1996; 39: 893-8.

64. Simillis C., Purkayastha S., Yamamoto T., Strong S.A., Darzi A.W., Tekkis P.P. A meta-analysis comparing conventional end-to-end anastomosis vs. other anastomotic configurations after resection in Crohn’s disease. Dis. Colon Rectum. - 2007; 50 (10): 1674-87.

65. Stocchi L., Milsom J.W., Fazio V.W. Long-term outcomes of laparoscopic versus open ileocolic resection for Crohn’s disease: follow-up of a prospective randomized trial. Surgery. - 2008; 144: 622-7.

66. Tekkis P.P., Purkayastha S., Lanitis S., Athanasiou T., Heriot A.G., Orchard T.R. et al. A comparison of segmental vs. subtotal/total colectomy for colonic Crohn’s disease: a meta-analysis. Colorectal Dis. - 2006; 8: 82-90.

67. Vorobiev G.I., Bolikhov K.V., Romanov R.I., Vardanyan A.V., Laparoscopic ileostomy as the stage of surgical treatment complicated Crohn’s disease of the colon. Proktologia. - 2008, 9, р. 145.

68. Byrne C.M., Solomon M.J., Young J.M., Selby W., Harrison J.D. Patient preferences between surgical and medical treatment in Crohn’s disease. Dis. Colon Rectum. - 2007; 50: 586-97.

69. Воробьев Г.И., Михайлова Т.Л., Болихов К.В., Варданян А.В. Эффективность илеостомии в лечении пациентов с тяжелой формой болезни Крона толстой кишки. Материалы научно-практической конференции «Актуальные проблемы гастроэнтерологии» (Василенковские чтения). - М., 2010. -с. 34.

70. Tichansky D., Cagir B., Yoo E., Marcus S.M., Fry R.D. Strictureplasty for Crohn’s disease: metaanalysis. Dis Colon Rectum. - 2000; 43: 911-9.

71. Reese G.E., Purkayastha S., Tilney H.S., von Roon A. Yamamoto T., Tekkis P.P. Strictureplasty vs. resection in small bowel Crohn’s disease: an evaluation of short-term outcomes and recurrence. Colorectal Dis. - 2007; 9: 686-94.

72. Yamamoto T., Fazio V.W., Tekkis P.P. Safety and efficacy of strictureplasty for Crohn’s disease: a systematic review and meta-analysis. Dis. Colon Rectum. - 2007; 50: 1968-86.

73. Caprilli R., Gassull M.A., Escher J.C. et al. European evidence based consensus on the diagnosis and management of Crohn’s disease: special situations. Gut. - 2006; 55 Suppl 1: i36-58.

74. Dietz D.W., Laureti S., Strong S.A., Hull T.L., Church J., Remzi F.H. et al. Safety and longterm efficacy of strictureplasty in 314 patients with obstructing small bowel Crohn’s disease. J. Am. Coll. Surg. - 2001; 192: 330-7.

75. Щукина О.Б. Перианальная болезнь Крона: диагностика и медикаментозная терапия. Фарматека. - 2008. - № 13. - с. 22-30.

76. Keighley M.R., Allan R.N. Current status and influence of operation on perianal Crohn’s disease. Int. J. Colorectal Dis. - 1986; 1: 104-7.

77. Tang L.Y., Rawsthorne P., Bernstein C.N. Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin. Gastroenterol. Hepatol. - 2006; 4: 1130-4.

78. Шелыгин Ю.А., Халиф И.Л., Кашников В.Н., Болихов К.В., Варданян А.В. Илеостомия в лечении болезни Крона толстой кишки с перианальными поражениями. «Колопроктология». - 2011. -№3 (37). - с. 133.

79. Vardanyan A.V., Khalif I.L., Kashnicov V.N., Mikhailova T.L., Bolikhov K.V. Ileostomy effectiveness in the treatment of the patients with the severe form of perianal Crohn’s disease. Falk Symposium 179, September 30 - October 1, 2011. Brussel, Belgium, р. 56.

80. Prantera C., Zannoni F., Scribano M.L. et al. An antibiotic regimen for the treatment of active Crohn’s disease: a randomized, controlled clinical trial of metronidazole plus ciprofloxacin. Am. J. Gastroenterol. - 1996; 91: 328-32.

81. van Dongen L.M., Lubbers E.J.C. Perianal fistulas in patients with Crohn’s disease. Arch. Surg. - 1986; 121: 1187-90.

82. Yamamoto T., Allan R.N., Keighley M.R. Effect of fecal diversion alone on perianal Crohn’s disease. World J. Surg. - 2000; 24: 1258-62.

83. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn’s disease. Gastroenterology. - 1990; 99: 956-63.

84. Loftus Jr.E.V. Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. Gastroenterology. -2004; 126 (6): 1504-17.

85. Головенко А.О., Халиф И.Л., Головенко О.В. Профилактика послеоперационных рецидивов болезни Крона. Колопроктология. - 2012. - №4. -с. 40-48.

86. Peyrin-Biroulet L. et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn’s disease: a meta-analysis. Am. J. Gastroenterol. - 2009. 104 (8): p. 2089-96.

87. Regueiro M., Schraut W., Baidoo L., Kip K.E., Sepulveda A.R., Pesci M. et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. - 2009; 136: 441-50.

88. Terdiman J.P. Prevention of postoperative recurrence in Crohn’s disease. Clin. Gastroenterol. Hepatol. - 2008. 6 (6): p. 616-20.

89. Papamichael K. et al., Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn’s disease: a prospective, two-year, single center, pilot study. J. Crohns Colitis. - 2012. 6 (9): p. 924-31.

90. Regueiro M. et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. - 2009. 136 (2): p. 441-50 e1; quiz 716.

91. Loly C., Belaiche J., Louis E. Predictors of severe Crohn’s disease. Scand. J. Gastroenterol. - 2008; 43: 948-54.

92. Rahier J.F. et al. European evidence-based Consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J. Crohns Colitis. - 2009. 3 (2): p. 47-91.

93. Froslie K.F., Jahnsen J., Moum B.A., Vatn M.H. Group I. Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology. - 2007; 133: 412-22.

94. Gert Van Assche, Axel Dignass, Julian Panes et al. The second European evidence-based consensus on the diagnosis and management of Crohn’s disease: Definitions and diagnosis. Journal of Crohn’s and Colitis. - 2010; 4, 7-27.

95. OCEBM Levels of Evidence Working Group. «The Oxford 2011 Levels of Evidence». Oxford Centre for Evidence-Based Medicine. http://www.cebm.net/ ocebm-levels-of-evidence